Abstract

Apremilast (APR) is one of the drugs used for the treatment of patients with several immune- inflammatory conditions. Currently, the APR is available for the treatment of psoriasis and psoriatic arthritis. This research was aimed to develop the bio-analytical method for estimation of APR and its bioequivalence and pharmacokinetics using the RP-HPLC-UV method. The method was as per USFDA guidelines and analyzing APR in rat plasma by oral administration in rats. Aplex 30 mg tablet was taken as a reference product to evaluate the pharmacokinetic profile of the Alizap 30 mg tablet which was taken as a test product. The Cmax for the test product and reference product was found to be 154.85±1.34 and 168.54±1.78 ng/ml respectively. The tmax for test and reference product was found to be 15±0.17 min respectively. AUC0-t for test and reference product was found to be 32248.52±8.10 and 33746.83±17.64 ng/ml. AUC0-∞ for test and reference product was found to be 32248.52±10.52 and 42210.61±14.32 ng/ml respectively. The T1/2 for test product and reference product was found to be 134.45±1.30 and 175.87±1.47 respectively. The pharmacokinetic study shows no significant (p > 0.05) difference by statistical analysis between two products and hence Aplex 30 mg (Reference product) was found to be bioequivalent to Alizap 30 mg (Test product).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call